about
Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesionsThe variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factorsThe anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signalingB-Raf and the inhibitors: from bench to bedsideMain roads to melanomaBRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status.Mutations of PIK3CA in gastric adenocarcinomaMelanoma: from melanocyte to genetic alterations and clinical optionsThe RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective mannerSystemic treatments for metastatic cutaneous melanomaEpidermal growth factor receptor (EGF-R) inhibitors for metastatic colorectal cancerModulation of the cancer cell transcriptome by culture media formulations and cell densityDisruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumorsMLK3 is required for mitogen activation of B-Raf, ERK and cell proliferationGenetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cellsSelective role for RGS12 as a Ras/Raf/MEK scaffold in nerve growth factor-mediated differentiationRelief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomasIQGAP1 modulates activation of B-RafDistinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signallingRaf family kinases: old dogs have learned new tricksBrn-2 expression controls melanoma proliferation and is directly regulated by beta-cateninRegulation of RAF activity by 14-3-3 proteins: RAF kinases associate functionally with both homo- and heterodimeric forms of 14-3-3 proteinsPI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancerThe RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cellsRecurrent BRAF mutations in Langerhans cell histiocytosisSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenibClinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaInactivation of Icmt inhibits transformation by oncogenic K-Ras and B-RafThe Brn-2 transcription factor links activated BRAF to melanoma proliferationAnalysis of the genome to personalize therapy for melanomaSorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cellsComplexity in KSR function revealed by Raf inhibitor and KSR structure studiesMolecular biology of lung cancerThe Cancer Genome Atlas Pan-Cancer analysis projectBRAF mutations in hairy-cell leukemiaMolecular biology of lung cancer: clinical implicationsInternational network of cancer genome projects.Molecular origins of cancer: Molecular basis of colorectal cancerCRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutationsPolymorphisms in the syntaxin 17 gene are not associated with human cutaneous malignant melanoma
P2860
Q17577870-AA3466CA-E841-4733-885D-0D03C1F89510Q27902869-9F209040-B23C-4C21-A51E-63445874CE94Q28334584-A662C158-519A-42A5-A29A-E4E57926424FQ28334700-A85494A9-AD81-4334-8F78-58DEBF9D1D12Q28519412-F9FC0CC6-258A-4B95-BF94-3FA234CEDB5CQ51838638-7E89B6AB-F3D6-430E-8C07-F91D3FF4B7E4Q54603001-75F0D72B-2131-4337-8172-3B1A3C4D7C79Q54605986-AF55A96D-E96F-4DEF-A262-679C00DC422FQ54606055-2B99F8FC-85EF-4ED2-87A3-5174115428B8Q54606245-F83AAD7E-E309-4DC2-8709-556BE7778F88Q54606435-94751820-87CF-43F7-92D8-B0D81A907DEAQ54606441-6E84F90D-D219-4000-A277-A6860F66557DQ54749551-D51628E9-3921-4679-B769-3823B61C7419Q54749799-0C1CECB5-6B02-429A-96E6-F88B3A0EE5F9Q54795836-F99D7677-EC5D-4E18-908B-5213E66D58C9Q54808423-A812391F-289A-4D37-A479-03AA4DF074C0Q54808427-6EC63F16-3530-49F8-A9C7-F21FDDC383B5Q54809249-D8D492B5-E45D-4B73-9528-9BB6C7C00136Q54809269-926CEE27-2AF5-4A5A-82AD-257819482337Q54809270-0A46829D-308B-4238-8C50-44DE7EAF833AQ54812102-FC4AA862-09BF-4D37-8D15-D0A1E4F7E586Q54813267-F1D93E42-8C2B-4D3C-8417-964D6BE219B0Q54814074-C80E213D-0F27-443C-AF2F-B4630CBED65DQ54814132-F0532ECF-1107-46BB-814E-AFC2B794BEA7Q54814145-4F001B57-1998-4FE1-993D-219F53006234Q54814154-02FFD100-391A-495E-888C-69F7A7DC21B3Q54814157-E313722F-1978-4DB7-85A3-63368A536715Q54814270-5F32836C-B794-4F21-B120-10AEC27FF53BQ54814695-36AAE24D-0B10-4B33-B58F-2825E29CC5FFQ54817171-8583BB33-6144-48A3-AE57-83E42EF03317Q54831148-7B9C395E-490B-4788-ACCB-ADF450E278A8Q54831578-88D16826-EA67-4B6D-BCCF-15284D22FE52Q54835343-27746A88-455B-459A-A82B-A7155C4617AAQ54835514-5C391B85-B983-4338-BC7F-7402152D642FQ54871617-1B7CE1A1-A0F4-4CB4-8700-CEF69A366EFEQ54882246-27A270B8-35DF-47D0-A6B3-9B87C66463F2Q54882789-81ECDEFF-24C9-4363-B9F8-8FB7C2F48A07Q54889913-3E8FA7C4-477B-449C-A209-8B720F976B92Q54889975-1D065A6C-31D9-4842-8F48-FE735DF9BF4EQ54890155-E006BA36-427A-4083-A122-7138CAE64A74
P1343
Q21004109-5B49D4E0-2CCB-4550-A2C9-64FDF46B25BDQ21092455-72554A4B-41E0-431F-BA8A-7069280296B9Q21133611-4BF92DF8-6610-4168-BFD7-2579436BBD28Q21198860-A3E0A8F8-0ABB-4437-B4C3-E14DEE0F849CQ21245465-156FAC1C-EC65-4826-A562-CD24AF54EB7EQ21245742-6383CA82-17A4-4CAF-B6E0-E0C284DF9D15Q21261219-FEE7B781-107A-4364-BD8D-4E42CC3A81E5Q21284811-CBCD5391-F8A7-448F-9943-0C1447B872C8Q21629049-ABD93210-5EA3-467C-97D9-D432AF4E1F14Q24194804-80CB2B30-B4AF-465D-B3EE-3C0BF23912C3Q24243806-5C5493F6-F956-44FC-8402-834565C7A033Q24273332-B173C62C-F03E-42B0-B90D-116F48A863ECQ24294914-EB35B6A2-996A-47D7-A17F-BDA34131D462Q24299564-BEEB5EE1-CB68-4777-B9A1-1DCD42C04360Q24300674-408D4966-748C-4365-8857-6FFB5268724BQ24300711-D9ACACC9-2D22-4B1A-A3C4-E2A884D56B2DQ24303940-D3FA3C70-176A-4513-88E9-AD151471AD8EQ24309982-0EA39821-F5C7-4B26-B229-5B6A170CE903Q24314807-3CD9311E-9B27-4015-BD54-EE3898525C22Q24316181-8C16E663-A9EE-47F9-B1FE-D4A57B06BF78Q24317170-38E21D54-0AC7-4C56-83F2-1A5E3A570529Q24320264-92587837-DAC9-4DF0-B6AE-9EB7D2BA1FABQ24338724-731892ED-0C85-4094-B321-9E5AC8362111Q24519206-63041B08-BA2C-4F08-A119-997359BA5930Q24594344-C76FD29C-60D8-4B81-8854-EE3F2724CD38Q24594790-0A8DE7AC-CB3F-4ADF-A6E9-86399F3D5E15Q24597152-D70B61FD-DA54-4167-B34B-34B0B3B73DAFQ24598824-07B6583C-877E-41E2-96F2-7AA24A24C445Q24599712-9EF60AEA-364A-4D38-B021-EA3685EA2EDBQ24601008-46162968-329A-4252-962D-C014A2584D19Q24602021-A55C2511-E142-4388-B30A-DA960EF9A60AQ24603489-A2A800B1-8A90-46B1-817B-E510613CE80BQ24606677-76F57F21-C0C7-44AC-806F-C44988B05A1CQ24606808-B2FAB6CA-5860-43A6-9176-6E3557EFDDF0Q24609980-69D6FA80-1CAF-4AE6-9054-8ED6AF88F75FQ24610335-D55F650F-EDCB-4366-BBBA-29DCEB431700Q24611474-9FED826C-B99A-497F-8A12-E3E4A360DACAQ24617331-C3EBE63B-2FC1-4EB0-BFAD-5D558E77439AQ24618486-7B6DEFC2-84D5-4845-9961-FF69722D35A6Q24619042-DC319C07-FF30-4F00-808C-B0EA44F34E92
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Mutations of the BRAF gene in human cancer
@ast
Mutations of the BRAF gene in human cancer
@en
Mutations of the BRAF gene in human cancer
@nl
type
label
Mutations of the BRAF gene in human cancer
@ast
Mutations of the BRAF gene in human cancer
@en
Mutations of the BRAF gene in human cancer
@nl
prefLabel
Mutations of the BRAF gene in human cancer
@ast
Mutations of the BRAF gene in human cancer
@en
Mutations of the BRAF gene in human cancer
@nl
P2093
P2860
P4510
P50
P3181
P356
P1433
P1476
Mutations of the BRAF gene in human cancer
@en
P2093
Adrian Parker
Adrienne Flanagan
Andrew Nicholson
Antonio Cossu
Barbara L Weber
Barry A Gusterson
Catherine Mould
Charles Cox
Christopher J Marshall
Claire Stevens
P2860
P2888
P304
P3181
P356
10.1038/NATURE00766
P407
P50
P577
2002-06-27T00:00:00Z
P5875
P6179
1023536940